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Brief CommunicationIndoprofen Upregulates
the Survival Motor Neuron Protein
through a Cyclooxygenase-Independent Mechanism
Introduction
Spinal muscular atrophy (SMA) is an autosomal reces-
sive disease characterized by rapid degeneration of
lower motor neurons in the anterior horn of the spinal
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from an SMN2-Minigene-Reporter Construct
We developed a high-throughput reporter assay de-
signed to detect SMN production. We used C33a cells
Summary stably expressing an SMN-minigene with luciferase re-
porter [13] that consisted of exons 6 through 8 and
Most patients with the pediatric neurodegenerative intervening introns, for either SMN1 or SMN2. Lucifer-
disease spinal muscular atrophy have a homozygous ase, the reporter gene’s product, is only produced when
deletion of the survival motor neuron 1 (SMN1) gene, proper splicing and translation occurs.
but retain one or more copies of the closely related We tested 20,000 compounds from a combinatorial
SMN2 gene. The SMN2 gene encodes the same protein library, 1040 compounds from a National Institute of
(SMN) but produces it at a low efficiency compared Neurological Disorders and Stroke (NINDS) library, 2337
with the SMN1 gene. We performed a high-throughput compounds from our Annotated Compound Library [14],
screen of 47,000 compounds to identify those that and 23,685 compounds from our TIC Library, which is
increase production of an SMN2-luciferase reporter a composite of compounds purchased from TimTec,
protein, but not an SMN1-luciferase reporter protein. IBS, and ChemBridge that were selected for specific
Indoprofen, a nonsteroidal anti-inflammatory drug properties, including stereochemical complexity [11].
(NSAID) and cyclooxygenase (COX) inhibitor, selec- We discovered that indoprofen significantly increased
tively increased SMN2-luciferase reporter protein and reporter activity from SMN2-luc cells relative to SMN1-
endogenous SMN protein and caused a 5-fold increase luc cells (Figures 1 and 2). The most effective concentra-
in the number of nuclear gems in fibroblasts from SMA tion, 2.8g/ml (10 M, MW 281.3), resulted in a 3-fold
patients. No other NSAIDs or COX inhibitors tested increase in luminescence. The raw data is available in
exhibited this activity. the Supplemental Data of our companion paper in this
issue [11] (available online at http://www.chembiol.com/
cgi/content/full/11/11/1489/DC1/).
*Correspondence: stockwell@biology.columbia.edu
To find related active compounds, we tested those7Current address: Broad Institute of Harvard and Massachusetts
with structures similar to indoprofen, including NSAIDs,Institute of Technology, 320 Charles Street, Cambridge, Massachu-
setts 02141. and found none that increased luminescence. Com-
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tained some degree of activity and selectivity, but this
may have been due to simple hydrolysis in cells and
generation of indoprofen (Figure 1).
Despite the noteworthy increase in SMN2-minigene-
reporter activity, real-time RT-PCR using SMA patient
fibroblasts failed to show an increase in the ratio of full-
length to truncated transcripts, or in the absolute level
of transcripts following indoprofen treatment (data not
shown). Considering indoprofen’s selective activity for
SMN2-luc, it is unlikely that indoprofen is acting post-
translationally, as both SMN1-luc and SMN2-luc encode
the same protein. We propose that indoprofen has a
pre- or cotranslational effect on protein production from
SMN2, through a cyclooxygenase-independent mecha-
nism. For example, it is possible that indoprofen, resem-
bling a nucleotide, binds to the SMN2 pre-mRNA and
displaces proteins that reduce the rate of translation.
We sought evidence as to whether indoprofen also af-
fects the level of endogenous SMN protein in human
cells.
Indoprofen Increases SMN Protein Level in Human
Type I SMA Patient Fibroblasts
To assess whether indoprofen treatment affected SMN
protein production, we treated type I SMA patient fibro-
blasts (3813) with indoprofen and assessed protein level
by Western blotting (Figure 2). We treated 3813 cells
with 5 and 20 M indoprofen for 3 days with daily media
and compound changes, even though liquid chromatog-
raphy-mass spectroscopy (LC-MS) revealed that there
was no significant degradation of indoprofen over 4 days
in cell culture medium (data not shown). Both concentra-
tions of indoprofen treatments yielded similar effects
on SMN protein increase, although occasionally higher
levels were observed from either treatment concentra-
tion (Figure 2). Combining data from both treatments,
indoprofen-treated cells resulted in a mean 13% in-
crease in SMN protein production versus untreated cells
(independent, one-tailed t test; n  17 [9 treated sam-
ples, 8 control samples],   15, p  0.014).
Indoprofen Increases Number of Nuclear Gems
in Human Type I SMA Patient Fibroblasts
The increase in SMN protein production led us to inquire
about the effect of indoprofen on the overall number of
Figure 1. Indoprofen and Related Compounds: Chemical Structures
gems—punctate structures in the nucleus. The numberand Maximum Percent Luminescence Enhancement from SMN1 and
of gems (short for “Gemini of coiled [Cajal] bodies”)SMN2 Minigene-Reporter Constructs for Treated versus Untreated
directly correlates with SMN protein production [5], andCells
they are found in many adult cell types (especially neu-(A) Indoprofen; SMN1: 44%, SMN2: 184%. (B) Ibuprofen; SMN1:
5.6%, SMN2: 0.8%. (C) Ketoprofen; SMN1: 30%, SMN2: 21%. rons) and in all fetal tissues. Fibroblasts from normal
(D) Suprofen; SMN1: 4.0%, SMN2: 5.0%. (E) Aspirin; patients, SMA carriers, and type I SMA patients have
SMN1: 5.1%, SMN2: 3.0%. (F) Acetaminophen; SMN1: 17%, 80 gems,40 gems, and1 to 2 gems per 100 nuclei,
SMN2: 9.5%. (G) Isoindolinone; SMN1: 18%, SMN2: 21%. (H) Es- respectively [5].terified indoprofen derivatives. R  methyl; SMN1: 38%, SMN2:
We treated human type I SMA fibroblasts (2806) with72%. R  ethyl; SMN1: 18%, SMN2: 98%. R  isopropyl; SMN1:
indoprofen (5 and 15 M) to observe changes in gem18%, SMN2: 70%. The isoindolinone group (“indo”) is shown in
orange, and the phenylpropionic acid group (“profen”) is shown in count. Both indoprofen treatments yielded a significant
blue. All chiral compounds were racemic mixtures. increase in gem count (5 M: independent, one-tailed t
test; n  17 [8 treated, 9 untreated],   15, p  6.9 
104 and 15 M: independent, one-tailed t test; n  16
[7 treated, 9 untreated],  14, p 1.7 104) (Figure 2).pounds with only the 2-phenylpropionic acid group or
the isoindolinone group did not enhance luminescence. Pooling the two treatments also generated a significant
result (independent, one-tailed t test; n 24 [15 treated,Methyl, ethyl, and isopropyl esters of indoprofen re-
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Figure 2. Indoprofen Increases Minigene-
Reporter Luminescence, SMN Protein Level,
and Number of Nuclear Gems
(A) C33a cells with a minigene-reporter con-
struct containing either SMN1 (red) or SMN2
(blue) treated with indoprofen. A similar result
was obtained in a mouse neuronal cell line
(NSC34) (data not shown).
(B) Aspirin (acetylsalicylic acid), acetamino-
phen (4-acetamidophenol), and ibuprofen
were tested in c33a cells with the same con-
structs as in (A).
(C) Type I SMA patient fibroblasts (13) with
no SMN1 have less SMN protein than carrier
fibroblasts (14) that have 1 copy of SMN1.
NSC34, a mouse neuronal cell line, cells (34)
with two copies of SMN1 exhibit an effect
that is visually indistinguishable from carrier
fibroblasts.
(D) Indoprofen-treated cells had a mean 13%
increase in SMN protein production over un-
treated cells (independent, one-tailed t test;
n  17,   15, p  0.0139) as determined
by densitometric analysis. Indoprofen-treated
samples and control sample are noted. An
initiation factor (eIF-4e) is shown as a loading
control.
(E) Indoprofen treatment of type I SMA patient
fibroblasts (2806) results in an increase in
gem count when compared to nontreated
cells. Blue circles represent samples within
each treatment. Red squares represent the
mean number of gems per 100 nuclei within
each treatment (0 M: 1.3; 5 M: 6.5; and 15
M: 8.3).
9 untreated],   22, p  3.2  107]. Additionally, we ment. Consistent with previous rodent studies using 14C-
labeled indoprofen [15], liquid chromatography-masstested one other type I SMA fibroblast cell line (3813)
and one mouse fibroblast cell line (25). These cell lines spectrometry (LC-MS) revealed that no indoprofen was
present in brain tissue 4 hr after treatment (data notyielded comparable results to 2806 (see Supplemental
Data available online at http://www.chembiol.com/cgi/ shown). Indoprofen was found in the both the plasma
of the pregnant mice and their embryos one hour aftercontent/full/11/11/1489/DC1/).
treatment. Both routes of administration resulted in5.3
M indoprofen plasma concentration, while the IPEffect of Indoprofen in a Mouse Model of SMA
In an attempt to find a maximum effective dose, the method was shown to be more effective than gavage
at delivering indoprofen to embryonic tissue. An averagepharmacokinetics of indoprofen in mice were studied.
Pregnant mice were treated with a single dose of 20 concentration of 3.0 M indoprofen was found in em-
bryos of IP-treated mice at embryonic day 13 (E13).mg/kg of indoprofen, using either intraperitoneal (IP)
injection or oral gavage, to determine how much indo- We tested the effect of indoprofen on the viability of
SMA model mice, which lack murine Smn but containprofen enters the brain, blood, and embryo after treat-
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shortcomings, such as severe side effects [34], ex-Table 1. Numbers of Non-SMA and SMA Litters and Embryos
from Untreated and Indoprofen-Treated Mother Mice tremely short half-life [35, 36] or nonselectivity of mecha-
nism [37–39]. Indoprofen is an NSAID with minimal sideLitters
effects [40, 41] that may be worthy of study as a thera-
Non-SMA SMA peutic agent for SMA. As indoprofen is not modifying
Untreated 7 0 splicing, possible additive effects may result from com-
Indoprofen treated 4 3 bination treatment with other drugs. In addition, it may
serve as a chemical probe to identify proteins that regu-Embryos
late the production of SMN protein.
Non-SMA SMA
Untreated 57 0 Significance
Indoprofen treated 39 3
Chemical genetic screening approaches can be used
to discover both novel therapeutic agents and chemi-
a human SMN2 transgene (i.e., Smn/; TgSMN2/) cal tools for genetic diseases. We describe such an
[16]. To generate litters that contained 25% Smn/; approach for the pediatric genetic disease spinal mus-
TgSMN2/ mice, we mated Smn/; TgSMN2/ mice cular atrophy (SMA). We developed a high-throughput
with Smn/; TgSMN2/ mice. Our SMA model mice assay that detects production of an SMN-luciferase
were derived from the published transgenic model cre- reporter protein, and we used this assay to identify
ated in C57BL/6 and crossed with FVB (Taconic Labs) compounds that increase production of SMN protein
[16]. These mice were backcrossed once with a wild- in cells. In a screen of47,000 compounds, we discov-
type FVB mouse to generate our C57BL/6/FVB mice. ered that a nonsteroidal anti-inflammatory drug (indo-
We found that in this strain of Smn/; TgSMN2/, em- profen) increases endogenous SMN protein level in
bryos die at approximately embryonic day 11 (E11). type I SMA patient fibroblasts. Additionally, we found
To determine whether indoprofen could increase the that indoprofen caused a 5- to 6-fold increase in the
viability of these SMA model embryos, we treated such number of nuclear gems, an indicator of greater intra-
pregnant mice twice daily for the first 14 days of preg- cellular SMN protein concentration. No other NSAIDs
nancy by IP injection with 5 mg/kg indoprofen in phos- displayed this ability to upregulate SMN protein level.
phate buffered saline, the maximum dose that exhibited This suggests that SMN upregulation is not caused by
no toxicity within the 14 days. On embryonic day 14 inhibiting COX activity (the known target of NSAIDs).
(E14), we genotyped the embryos and ascertained the Finally, we found that indoprofen caused a trend to-
number of Smn/; TgSMN2/ (SMA genotype) embryos ward increased viability of SMA model mice. Indopro-
(Table 1). At E14, none of the 7 untreated litters harbored fen may prove to be a treatment for SMA, and it may
any SMA genotype embryos, whereas 3 of 7 indoprofen- serve as a chemical tool to identify novel proteins
treated litters harbored SMA genotype embryos (Fisher regulating SMN protein production.
Exact test,   1, p  0.096). Thus, there was a trend
in which indoprofen increased the viability of SMA model Supplemental Data
mice. As expected, indoprofen treatment significantly
Detailed experimental procedures are available as Supplemental Dataincreased the mean litter size from 5.7 embryos to 6.9
at http://www.chembiol.com/cgi/content/full/11/11/1489/DC1/.embryos (independent, one-tailed t test; n 14,   12,
p  0.040). There was also a trend in which indoprofen
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